Long-Term Follow-Up Confirms Efficacy of N-AVD in Hodgkin Lymphoma
Researchers sought to determine whether N-AVD would continue to show a high response rate in patients with early-stage, unfavorable Hodgkin lymphoma.
Researchers sought to determine whether N-AVD would continue to show a high response rate in patients with early-stage, unfavorable Hodgkin lymphoma.
Researchers sought to determine whether first-line brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine would yield favorable results in HL.
Hodgkin lymphoma patients treated with subdiaphragmatic radiation and/or procarbazine have an increased risk of developing colorectal cancer, a study suggests.
Researchers sought to determine whether a novel clinical prediction model would be able to determine patient prognosis in advanced-stage classical Hodgkin lymphoma.
Researchers sought to determine whether combining nivolumab with chemotherapy and radiotherapy would be effective in early-stage, unfavorable Hodgkin lymphoma.
Consolidation with up to 8 cycles of brentuximab vedotin plus nivolumab appears active in high-risk, relapsed/refractory Hodgkin lymphoma.
Event-free survival rate higher in pediatric patients, but no difference seen in the percentage of patients receiving involved-site radiation therapy.
The approval was based on data from the open-label phase 3 AHOD1331 trial.
Researchers sought to determine whether camidanlumab tesirine would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
Researchers sought to determine risk predictors for coronary heart disease and heart failure in Hodgkin lymphoma survivors who were aged 18 to 50 at diagnosis.